Vertex Pharmaceuticals Inc. has identified 4-phenyl-2-(1H-1,2,3-triazol-4-yl)piperidin-4-ol derivatives acting as apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of pancreatic cancer, focal segmental glomerulosclerosis and renal disorders.